April 24 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics (SWTX.O), opens new tab for about $3.5 ...

The two parties are discussing a deal around $47 per share, Merck said in a statement Thursday, confirming an earlier report in The Wall Street Journal. Merck said no final agreement had been made.